Regentis Biomaterials Ltd. (RGNT) Balance Sheet
RGNT balance sheet, 2025
December 31, 2025 · U.S. dollars$7.6M assets = $2.9M liabilities + $4.7M equity
Both columns are drawn to the same scale: what RGNT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
RGNT financial health
Descriptive bands, not a rating. Fiscal 2025.
RGNT balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.7M2022 | $7.6M2025 | +64.3%/yr | |
| Total liabilities | $43.8M2022 | $2.9M2025 | −59.7%/yr | |
| Shareholders’ equity | −$42.1M2022 | $4.7M2025 | — | |
| Cash & short-term investments | $1.2M2022 | $7.4M2025 | +81.2%/yr | |
| Total debt | $6.5M2022 | $7.4M2023 | +14.4%/yr | |
| Net cash (debt) | −$5.2M2022 | −$7.1M2023 | −$1.8M | |
| Working capital | −$892,0002022 | $4.7M2025 | +$5.6M | |
| Book value per share | −$8.532022 | $0.922025 | — | |
| Current ratio | 0.662022 | 2.652025 | +1.99 | |
| Shares outstanding | 4.9M2022 | 5.2M2025 | +1.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RGNT assets
RGNT liabilities and equity
RGNT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
RGNT balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $7.4M | $229,000 | $345,000 | $1.2M |
| Cash & equivalents | $7.4M | $229,000 | $345,000 | $1.2M |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $240,000 | $253,000 | $15,000 | $477,000 |
| Total current assets | $7.6M | $482,000 | $360,000 | $1.7M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 |
| Total assets | $7.6M | $482,000 | $360,000 | $1.7M |
| Liabilities | ||||
| Accounts payable | $266,000 | $252,000 | $353,000 | $206,000 |
| Total current liabilities | $2.9M | $6.5M | $3.1M | $2.6M |
| Long-term debt | $0 | $0 | $7.4M | $6.5M |
| Other long-term liabilities | $0 | $35.1M | $35.7M | $34.7M |
| Total liabilities | $2.9M | $41.6M | $46.3M | $43.8M |
| Shareholders' equity | ||||
| Retained earnings (deficit) | −$55.8M | −$42.1M | −$46.9M | −$42.8M |
| Total shareholders' equity | $4.7M | −$41.1M | −$45.9M | −$42.1M |
| Key figures | ||||
| Total debt | — | — | $7.4M | $6.5M |
| Net cash (debt) | — | — | −$7.1M | −$5.2M |
| Working capital | $4.7M | −$6.0M | −$2.8M | −$892,000 |
| Tangible book value | $4.7M | −$41.1M | −$45.9M | −$42.1M |
| Book value per share | $0.92 | −$7.94 | −$9.31 | −$8.53 |
| Shares outstanding | 5.2M | 5.2M | 4.9M | 4.9M |
| Current ratio | 2.65 | 0.07 | 0.11 | 0.66 |
| Quick ratio | 2.57 | 0.04 | 0.11 | 0.48 |
| Equity / assets | 62.3% | −8,527.8% | −12,751.4% | −2,449.7% |
| Dec '25 | Jun '25 | Dec '24 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $7.4M | $189,000 | $229,000 |
| Cash & equivalents | $7.4M | $189,000 | $229,000 |
| Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other current assets | $240,000 | $286,000 | $253,000 |
| Total current assets | $7.6M | $475,000 | $482,000 |
| Property, plant & equipment (net) | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 |
| Total assets | $7.6M | $475,000 | $482,000 |
| Liabilities | |||
| Accounts payable | $266,000 | $262,000 | $252,000 |
| Total current liabilities | $2.9M | $9.7M | $6.5M |
| Long-term debt | $0 | $0 | $0 |
| Other long-term liabilities | $0 | $35.1M | $35.1M |
| Total liabilities | $2.9M | $44.8M | $41.6M |
| Shareholders' equity | |||
| Retained earnings (deficit) | −$55.8M | −$45.4M | −$42.1M |
| Total shareholders' equity | $4.7M | −$44.3M | −$41.1M |
| Key figures | |||
| Working capital | $4.7M | −$9.2M | −$6.0M |
| Tangible book value | $4.7M | −$44.3M | −$41.1M |
| Book value per share | $0.92 | −$8.56 | −$7.94 |
| Shares outstanding | 5.2M | 5.2M | 5.2M |
| Current ratio | 2.65 | 0.05 | 0.07 |
| Quick ratio | 2.57 | 0.02 | 0.04 |
| Equity / assets | 62.3% | −9,333.1% | −8,527.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed —); data from EODHD.
RGNT financial position
At the end of fiscal 2025 (December 31, 2025), Regentis Biomaterials had total assets of $7.6 million (up 1,480.5% from a year earlier), total liabilities of $2.9 million and shareholders' equity of $4.7 million. Its current ratio was 2.65.
Related: RGNT income statement, RGNT cash flow statement, RGNT key metrics. See the RGNT stock overview for the latest quote and news.
RGNT balance sheet FAQ
What are Regentis Biomaterials's total assets?
Regentis Biomaterials reported total assets of $7.6 million at the end of fiscal 2025 (December 31, 2025), compared with $0.5 million a year earlier.
How much cash does Regentis Biomaterials have?
Regentis Biomaterials held $7.4 million in cash and short-term investments at the end of fiscal 2025.
What is Regentis Biomaterials's book value?
Regentis Biomaterials's shareholders' equity (book value) was $4.7 million at the end of fiscal 2025, or $0.92 per share.
What is Regentis Biomaterials's current ratio?
Regentis Biomaterials had current assets of $7.6 million and current liabilities of $2.9 million, a current ratio of 2.65 (it can cover its short-term obligations).